Cue Biopharma, Inc. (CUE)
NASDAQ: CUE · Real-Time Price · USD
0.5801
-0.0899 (-13.42%)
At close: Apr 22, 2026, 4:00 PM EDT
0.5999
+0.0198 (3.41%)
After-hours: Apr 22, 2026, 7:58 PM EDT
Cue Biopharma Revenue
In the year 2025, Cue Biopharma had annual revenue of $27.47M with 195.75% growth. Cue Biopharma had revenue of $21.94M in the quarter ending December 31, 2025, with 1,292.26% growth.
Revenue (ttm)
$27.47M
Revenue Growth
+195.75%
P/S Ratio
2.06
Revenue / Employee
$947,103
Employees
29
Market Cap
56.65M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 27.47M | 18.18M | 195.75% |
| Dec 31, 2024 | 9.29M | 3.80M | 69.16% |
| Dec 31, 2023 | 5.49M | 4.25M | 340.96% |
| Dec 31, 2022 | 1.25M | -13.70M | -91.67% |
| Dec 31, 2021 | 14.94M | 11.79M | 373.68% |
| Dec 31, 2020 | 3.15M | -304.00K | -8.79% |
| Dec 31, 2019 | 3.46M | 2.32M | 202.67% |
| Dec 31, 2018 | 1.14M | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ImmuCell | 27.64M |
| MindWalk Holdings | 20.70M |
| ImageneBio | 800.00K |
| Spruce Biosciences | 697.00K |
| MediciNova | 409.66K |
| iBio, Inc. | 300.00K |
CUE News
- 12 hours ago - Cue Biopharma Announces 1-for-30 Reverse Stock Split - GlobeNewsWire
- 12 days ago - Cue Biopharma Receives $7.5M Milestone Payment From Boehringer Ingelheim - Benzinga
- 14 days ago - Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License Agreement - GlobeNewsWire
- 26 days ago - Cue Biopharma Announces CEO Transition - GlobeNewsWire
- 27 days ago - Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026 - GlobeNewsWire
- 5 weeks ago - Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - GlobeNewsWire
- 6 weeks ago - Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026 - GlobeNewsWire
- 2 months ago - Cue Biopharma Announces Preclinical Safety and Tolerability Data for CUE-401 for the Treatment of Autoimmune and Inflammatory Diseases - GlobeNewsWire